Matinas BioPharma Holdings Beheer

Beheer criteriumcontroles 3/4

De CEO Matinas BioPharma Holdings is Jerry Jabbour, benoemd in Mar2016, heeft een ambtstermijn van 8.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.60M, bestaande uit 37.4% salaris en 62.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.18% van de aandelen van het bedrijf, ter waarde $ 5.53K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.1 jaar en 6.8 jaar.

Belangrijke informatie

Jerry Jabbour

Algemeen directeur

US$1.6m

Totale compensatie

Percentage CEO-salaris	37.4%
Dienstverband CEO	8.7yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	6.1yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Feb 23

Analyse CEO-vergoeding

Hoe is Jerry Jabbour's beloning veranderd ten opzichte van Matinas BioPharma Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$23m
Mar 31 2024	n/a	n/a	-US$23m
Dec 31 2023	US$2m	US$598k	-US$23m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$2m	US$575k	-US$21m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$4m	US$545k	-US$24m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$3m	US$500k	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$445k	-US$18m
Sep 30 2019	n/a	n/a	-US$16m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$15m
Dec 31 2018	US$1m	US$366k	-US$15m
Sep 30 2018	n/a	n/a	-US$15m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$16m
Dec 31 2017	US$1m	US$299k	-US$33m

Compensatie versus markt: De totale vergoeding ($USD 1.60M ) Jerry } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Jerry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jerry Jabbour (50 yo)

8.7yrs

Tenure

US$1,599,551

Compensatie

Mr. Jerome D. Jabbour, also known as Jerry, J. D., Co-founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016....

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jerome Jabbour	Co-Founder	8.7yrs	US$1.60m	0.18% $ 5.5k
Keith Kucinski	Chief Financial Officer	5.8yrs	US$626.60k	0.038% $ 1.1k
Frank Calamusa	Executive Director and Head of Manufacturing & Supply Chain	6.1yrs	geen gegevens	geen gegevens

6.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van MTNB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jerome Jabbour	Co-Founder	6.7yrs	US$1.60m	0.18% $ 5.5k
Herbert Conrad	Independent Director	11.3yrs	US$141.50k	1.87% $ 56.4k
James Scibetta	Independent Director	11yrs	US$155.00k	0.26% $ 7.8k
David Perlin	Member of Scientific Advisory Board	9.3yrs	geen gegevens	geen gegevens
Natasha Giordano	Independent Director	4.2yrs	US$145.50k	geen gegevens
Matthew Wikler	Independent Director	6.8yrs	US$136.00k	0.12% $ 3.5k
Eric Ende	Independent Chairman of the Board	7.6yrs	US$159.00k	0.057% $ 1.7k
J. Craft	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Kathryn Corzo	Independent Director	3yrs	US$140.00k	geen gegevens
Peter Pappas	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Oliver Cornely	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Dimitrios Kontoyiannis	Member of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MTNB wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

Matinas BioPharma Holdings Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Matinas BioPharma Holdings, Inc. Announces Executive Changes

Insufficient new directors

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Insufficient new directors

Recent updates

New major risk - Market cap size

Matinas BioPharma Holdings, Inc. Announces Executive Changes

New minor risk - Share price stability

Matinas BioPharma Holdings, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program

New major risk - Revenue and earnings growth

Matinas BioPharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

New minor risk - Shareholder dilution

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

New major risk - Share price stability

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation

Matinas BioPharma Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA

Third quarter 2023 earnings released: US$0.028 loss per share (vs US$0.025 loss in 3Q 2022)

Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Matinas BioPharma Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient’s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203

No longer forecast to breakeven

Insufficient new directors

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases

Matinas BioPharma Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus revenue estimates fall by 90%

Matinas BioPharma Holdings, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 46%

Forecast to breakeven in 2025

Price target decreased to US$2.75

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 41,381%

Price target decreased to US$2.75

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Insufficient new directors

Forecast to breakeven in 2024

Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final Cohort of Patients in the Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis

Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

Consensus forecasts updated

Consensus revenue estimates increase to US$2.48m

Forecast to breakeven in 2025

Consensus revenue estimates increase to US$1.27m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.13 loss in FY 2019)

Price target decreased to US$3.08

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

Price target raised to US$3.75

Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

New 90-day high: US$1.47

Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology

Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer

New 90-day high: US$0.90

Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Analysts increase revenue estimates to US$1.37m